secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-01-28T23:59:59+00:00
Accession:  0001867096-22-000023
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris files Strongbridge unaudited 9M 2021 financials: net loss $31.6M, rev $29.9M
--------------------------------------------------------------------------------

- Strongbridge nine months ended Sep 30, 2021: net loss $31.6M vs $33.1M prior-year.
- Revenue $29.9M vs $22.5M prior-year, primarily from Keveyis sales.
- Cash and equivalents $55.3M; accumulated deficit $337.2M as of Sep 30, 2021.
- Acquisition by Xeris closed Oct 5, 2021; filing satisfies SEC requirement for acquired company financial statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000023/0001867096-22-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000023/xers-20220128.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer